Pituitary Adenoma
Conditions
Brief summary
The images of patients with Pituitary adenoma were collected and analyzed based on the methods of radiomics.
Detailed description
Inclusion of pituitary adenoma patients diagnosed clinically or pathologically 1. Clinical data and pre-treatment imaging data of included patients (DICOM format) 2. Determine the subtype diagnosis of pituitary adenoma based on the patient's clinical and pathological data 3. Collect relevant data of patients before and after treatment 4. Using radiomics methods, extract radiomic features of patients and construct a radiomic model for predicting the diagnosis and treatment response of pituitary adenomas
Interventions
PROCEDUREsurgery of pituitary adenomas
evaluate pathological type and treatment effect after treatment
Sponsors
Beijing Tiantan Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Gender unlimited, 18-80 years old; 2. Clinical diagnosis of Pituitary Adenoma and receive surgical treatment; 3. Received brain imaging; 4. informed consent signed
Exclusion criteria
1. Pregnant / lactating women 2. Contraindications of imaging examination 3. Lack of effective clinical data 4. MRI data before treatment cannot be obtained 5. Postoperative pathology not revealed pituitary adenoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence rate of pituitary adenoma | 1 year after treatment | The pituitary adenoma recurred 1 year after treatment. The recurrence was assessed by 3 aspects: (1)contrast enhanced MRI showed suspicious tumor growth, such as bone destruction; (2)signs and symptoms that had disappeared after treatment reappeared, such as pressing on nearby nerve tissue and some characteristic appearance; (3)endocrine indexes rose again after reaching the remission standard, iculding Prolactin(PRL)\>30 μg/L in Lactotroph adenoma; growth hormone (GH)\>2.5ng/ml in Somatotroph adenoma, serum cortisol\>800nmol/L at 8am in Corticotroph adenoma, while other types do not consider endocrine indicators. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathological type of pituitary adenomas | 1 week after treatment | The pathological examination was used to evaluated the type of pituitary adenoma. The pathological type was assessed by 2017 WHO standard, divided into Somatotroph adenoma, Lactotroph adenoma, Thyrotroph adenoma, Corticotroph adenoma, Gonadotroph adenoma, Null-cell adenoma and Plurihormonal and double adenomas. |
Countries
China
Outcome results
None listed